| Titre : | International Journal of Drug Policy, Vol.47 - September 2017 - Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy |
| Auteurs : | J. GREBELY ; J. BRUNEAU ; P. BRUGGMANN ; M. HARRIS ; M. HICKMAN ; T. RHODES ; C. TRELOAR, Éditeur scientifique |
| Type de document : | Bulletin : Périodique |
| Paru le : | 01/09/2017 |
| Année de publication : | 2017 |
| Format : | 1-246 |
| Langues: | Anglais |
| Discipline : | MAL (Maladies infectieuses / Infectious diseases) |
| Mots-clés : |
Thésaurus TOXIBASE HEPATITE ; TRAITEMENT ; ANTIVIRAUX ; USAGER ; INJECTION |
| Note de contenu : |
CONTENTS:
- Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. Capler R., Walsh Z., Crosby K., Belle-Isle L., Holtzman S., Lucas P., et al., p. 1-8. - Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. Horyniak D., Wagner K.D., Armenta R.F., Cuevas-Mota J., Hendrickson E., Garfein R.S., p. 9-17. - Animal house: University risk environments and the regulation of students' alcohol use. Wilkinson B., Ivsins A., p. 18-25. - Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy [Editorial]. Grebely J., Bruneau J., Bruggmann P., Harris M., Hickman M., Rhodes T., et al., p. 26-33. - Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. Bajis S., Dore G.J., Hajarizadeh B., Cunningham E.B., Maher L., Grebely J., p. 34-46. - Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses [Viewpoint]. Lazarus J.V., Safreed-Harmon K., Stumo S.R., Jauffret-Roustide M., Maticic M., Reic T., et al., p. 47-50. - Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Grebely J., Bruneau J., Lazarus J.V., Dalgard O., Bruggmann P., Treloar C., et al., p. 51-60. - High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention. Puzhko S., Roy E., Jutras-Aswad D., Artenie A.A., Fortier E., Zang G., et al., p. 61-68. - Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015. Graham S., Maher L., Wand H., Doyle M., Iversen J., p. 69-76. - Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. Iversen J., Grebely J., Catlett B., Cunningham P., Dore G.J., Maher L., p. 77-85. - Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs. Stephens D.B., Young A.M., Havens J.R., p. 86-94. - HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985-2015. van Santen D.K., van der Helm J.J., Lindenburg K., Schim van der Loeff M., Prins M., p. 95-101. - Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. Butler K., Day C., Sutherland R., van Buskirk J., Breen C., Burns L., et al., p. 102-106. - Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Scott N., Doyle J.S., Wilson D.P., Wade A., Howell J., Pedrana A., et al., p. 107-116. - Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands. Helsper C.W., Janssen M.P., van Essen G.A., Croes E.A., van der Veen C., de Wit A.G., et al., p. 117-125. - DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. Radley A., Tait J., Dillon J.F., p. 126-136. - Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals. Mah A., Hull M.W., DeBeck K., Milloy M.J., Dobrer S., Nosova E., et al., p. 137-143. - Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. Mukherjee T.I., Pillai V., Ali S.H., Altice F.L., Kamarulzaman A., Wickersham J.A., p. 144-152. - 'I didn't want to let it go too far.' The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. Marshall A.D., Grebely J., Dore G.J., Treloar C., p. 153-160. - Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'. Harris M., p. 161-168. - Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV? Panagiotoglou D., Krebs E., Min J.E., Olding M., Ahamad K., Ti L., et al., p. 169-176. - Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. Grebely J., Dalgard O., Cunningham E.B., Hajarizadeh B., Foster G.R., Bruggmann P., et al., p. 177-186. - Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. Mazhnaya A., Meteliuk A., Barnard T., Zelenev A., Filippovych S., Altice F.L., p. 187-195. - High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Norton B.L., Fleming J., Bachhuber M.A., Steinman M., DeLuca J., Cunningham C.O., et al., p. 196-201. - Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Mason K., Dodd Z., Guyton M., Tookey P., Lettner B., Matelski J., et al., p. 202-208. - Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Read P., Lothian R., Chronister K., Gilliver R., Kearley J., Dore G.J., et al., p. 209-215. - Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network. Morris L., Smirnov A., Kvassay A., Leslie E., Kavanagh R., Alexander N., et al., p. 216-220. - Tensions in relation: How peer support is experienced and received in a hepatitis C treatment intervention. Bonnington O., Harris M., p. 221-229. - Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. Midgard H., Hajarizadeh B., Cunningham E.B., Conway B., Backmund M., Bruggmann P., et al., p. 230-238. - Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. Artenie A.A., Zang G., Daniel M., Fortier E., Jutras-Aswad D., Puzhko S., et al., p. 239-243. |
| Domaine : | Drogues illicites / Illicit drugs |
| Cote : | Abonnement |
| Lien : | http://www.sciencedirect.com/science/journal/09553959/47 |
Dépouillements
Ajouter le résultat dans votre panier
Article : Périodique
S. BAJIS ;
G. J. DORE ;
B. HAJARIZADEH ;
E. B. CUNNINGHAM ;
L. MAHER ;
J. GREBELY
|
Background: The burden of hepatitis C virus (HCV) infection is escalating among people who inject drugs (PWID), yet testing and treatment remains suboptimal. The aim of this systematic review was to evaluate the effectiveness of interventions to[...]
![Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses [Viewpoint]](https://bdoc.ofdt.fr/img_cache/f4bb3e0a88cfa6a85701926b58f543fe.png)
Article : Périodique
J. V. LAZARUS ;
K. SAFREED-HARMON ;
S. R. STUMO ;
M. JAUFFRET-ROUSTIDE ;
M. MATICIC ;
T. REIC ;
E. SCHATZ ;
J. TALLADA ;
M. HARRIS ;
HEP-CORE STUDY GROUP
|
In 2016, the World Health Organization (WHO) called for the elimination of viral hepatitis as a public health threat and established the ambitious targets of achieving an 80% reduction in new infections and a 65% reduction in deaths from hepatit[...]
Nouveauté
![Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs [Commentary]](https://bdoc.ofdt.fr/img_cache/5b2fc2911f196cb9326a86c7de9e7b4f.png)
Article : Périodique
J. GREBELY ;
J. BRUNEAU ;
J. V. LAZARUS ;
O. DALGARD ;
P. BRUGGMANN ;
C. TRELOAR ;
M. HICKMAN ;
M. HELLARD ;
T. ROBERTS ;
L. CROOKS ;
H. MIDGARD ;
S. LARNEY ;
L. DEGENHARDT ;
H. ALHO ;
J. BYRNE ;
J. F. DILLON ;
J. J. FELD ;
G. FOSTER ;
D. GOLDBERG ;
A. R. LLOYD ;
J. REIMER ;
G. ROBAEYS ;
M. TORRENS ;
N. WRIGHT ;
I. MAREMMANI ;
B. L. NORTON ;
A. H. LITWIN ;
G. J. DORE ;
International Network on Hepatitis in Substance Users
|
Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among th[...]
Nouveauté
Article : Périodique
Background: HIV-positive people who use drugs (PWUD) start antiretroviral therapy (ART) later than other risk groups, and among HCV-positive PWUD, HCV treatment uptake is low. Nowadays, HCV direct-acting antivirals (DAAs) are available and reimb[...]
Nouveauté
Article : Périodique
C. W. HELSPER ;
M. P. JANSSEN ;
G. A. VAN ESSEN ;
E. A. CROES ;
C. VAN DER VEEN ;
A. G. DE WIT ;
N. J. DE WIT
|
Background: Hepatitis C virus infection (HCV) is a serious, but underdiagnosed disease that can generally be treated successfully. Therefore, a nationwide HCV awareness campaign was implemented in the Netherlands targeting people who inject drug[...]
Nouveauté
Article : Périodique
A. MAH ;
M. W. HULL ;
K. DEBECK ;
M. J. MILLOY ;
S. DOBRER ;
E. NOSOVA ;
E. WOOD ;
T. KERR ;
K. HAYASHI
|
Background: Knowledge of hepatitis C virus (HCV) is believed to be important in altering risk behaviour, improving engagement in care, and promoting willingness to initiate HCV treatment. We assessed factors associated with HCV knowledge and tre[...]
Nouveauté
Article : Périodique
A. A. ARTENIE ;
G. ZANG ;
M. DANIEL ;
E. FORTIER ;
D. JUTRAS-ASWAD ;
S. PUZHKO ;
J. BRUNEAU
|
Background: It is unclear whether treatment and care for hepatitis C virus (HCV) infection can help people who inject drugs (PWID) modify their injection drug use behaviours. This study examined changes in injection drug use among PWID with acut[...]
Nouveauté
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |
Accueil
